The global psoriasis drug market is experiencing explosive growth, projected to reach US$27.57 billion by 2034. Driven by increasing prevalence, R&D investment, and innovative treatments, this market analysis reveals key trends, leading players, and future projections.
Forensic Science Ireland’s (FSI) latest report reveals cannabis and its related products make up 42% of analyzed drug cases in 2023. The report highlights the increasing prevalence of semi-synthetic cannabinoids like HHC, which pose significant public health risks due to their unknown long-term effects and potential for contamination. This concerning trend underscores the need for tighter regulations and public awareness about the dangers of these legal yet potentially harmful substances.
The global market for Friedreich’s Ataxia drugs is projected to experience significant growth, reaching a value of US$ 3.49 billion by 2034. This growth is driven by increased investments in disease-modifying treatments and gene therapy, as well as supportive initiatives from governments and non-profit organizations. The market is expected to be dominated by North America, with a projected market share of 36.7% by 2034.
